News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
AstraZeneca PLC: Third Quarter and Nine Months Results 2009
October 29, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
STOCKHOLM--(BUSINESS WIRE)--AstraZeneca (STO:AZN) (LSE:AZN) - Third quarter revenue increased by 10 percent at constant exchange rates (CER) to $8,200 million.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
AstraZeneca
MORE ON THIS TOPIC
Layoff Tracker
Biogen axes ‘small number’ of Apellis roles after $5.6B buy
June 26, 2026
·
63 min read
·
BioSpace Editorial Staff
Pipeline
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
June 26, 2026
·
2 min read
·
Tristan Manalac
M&A
Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production
June 26, 2026
·
2 min read
·
Nick Paul Taylor
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
·
1 min read
·
Jennifer C. Smith-Parker
